期刊
CURRENT ONCOLOGY REPORTS
卷 16, 期 2, 页码 -出版社
SPRINGER
DOI: 10.1007/s11912-013-0368-7
关键词
Aflibercept.; Metastatic colorectal cancer.; Vascular endothelial growth factor.; Angiogenesis.; Evolving therapies
类别
资金
- NCI NIH HHS [K12 CA090625] Funding Source: Medline
Aflibercept ( known as ziv-aflibercept in the USA and sold under the trade name Zaltrap((R)) is a human recombinant fusion protein with antiangiogenic effects that functions as a decoy receptor to bind vascular endothelial growth factors A and B and placental growth factor. Its unique mechanism of action with respect to other agents targeting angiogenesis led investigators to speculate that it may be more ubiquitously efficacious in tumors highly dependent on pathologic angiogenesis for their growth. Despite encouraging preclinical studies in various tumor types, aflibercept has not been proven efficacious in most later-phase clinical studies. In fact, its only currently held US Food and Drug Administration indication is in metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin, and irinotecan for those patients previously treated with an oxaliplatin- containing chemotherapy regimen. Given aflibercept's toxicity profile and cost, further investigation is needed to better understand its mechanism of action and to discover predictive biomarkers for optimization of its appropriate use in treatment of cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据